



# GLAND PHARMA LIMITED

November 29, 2022

BSE Limited  
Surveillance Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Surveillance Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Clarification / Confirmation on news item appearing in “Media / Publication”- your e-mail dated 29<sup>th</sup> November, 2022**

This has reference to your e-mail and the letter dated 29<sup>th</sup> November, 2022 seeking clarification on the news item appearing in “Media / Publication” – Livemint.com dated November 29, 2022 captioned “Gland Pharma’s Chinese Owner mulls sale of drugmaker, shares jump”.

In this regard, we would like to clarify that Gland Pharma Limited (‘the Company’) is not aware of any such information that its Promoters – Fosun Pharma and / or its Parent, Fosun International is considering sale of shares of the Company. The Company is not in receipt of any communication in this regard from its Promoter(s) and is unable to comment on the same.

We are cognizant of our disclosure obligations under the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), and as and when matters arise that require disclosure, the Company will fully comply with its obligations under the SEBI Listing Regulations and make appropriate disclosures.

This news article will not have any bearing on the operations / business of the Company.

Please take the same on record.

Yours truly,  
**For Gland Pharma Limited**

**P Sampath Kumar**  
Company Secretary and Compliance Officer